Lourdes Calvo
About
Lourdes Calvo is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Lourdes Calvo has authored 102 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 52 papers in Cancer Research and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lourdes Calvo's work include Cancer Treatment and Pharmacology (54 papers), Breast Cancer Treatment Studies (47 papers) and HER2/EGFR in Cancer Research (36 papers). Lourdes Calvo is often cited by papers focused on Cancer Treatment and Pharmacology (54 papers), Breast Cancer Treatment Studies (47 papers) and HER2/EGFR in Cancer Research (36 papers). Lourdes Calvo collaborates with scholars based in Spain, Italy and United States. Lourdes Calvo's co-authors include Eva Carrasco, Emilio Alba, Aňa Lluch, Angélica Figueroa, Manuel Valladares‐Ayerbes, M. Blanco, Miguel Martín, Miguel Ángel Seguí, Mar Haz‐Conde and Luis Antón-Aparicio and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.
In The Last Decade
Lourdes Calvo
98 papers receiving 1.9k citations
Peers
Lourdes Calvo
G. Peruzzotti Italy
Laura Pizzuti Italy
Stephen P. Anthony United States
Cecilia Nisticò Italy
Taher Al‐Tweigeri Saudi Arabia
Volker Möbus Germany
Eleni Andreopoulou United States
Paola Papaldo Italy
Elizabeth Comen United States
Alexandra Thomas United States
Citations per year, relative to Lourdes Calvo Lourdes Calvo (= 1×)
peers
G. Peruzzotti
Countries citing papers authored by Lourdes Calvo
Since
Specialization
Citations
This map shows the geographic impact of Lourdes Calvo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lourdes Calvo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lourdes Calvo more than expected).
Fields of papers citing papers by Lourdes Calvo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lourdes Calvo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lourdes Calvo. The network helps show where Lourdes Calvo may publish in the future.
Co-authorship network of co-authors of Lourdes Calvo
This figure shows the co-authorship network connecting the top 25 collaborators of Lourdes Calvo. A scholar is included among the top collaborators of Lourdes Calvo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lourdes Calvo. Lourdes Calvo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
García, José Manuel Pérez, María Gión, Manuel Ruíz‐Borrego, et al.. (2024). Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 1101–1101.
2.
Pértega-Díaz, Sónia, et al.. (2023). Foot health and quality of life in women with breast cancer undergoing chemotherapy: a cross‐sectional study. Journal of Foot and Ankle Research. 16(1). 52–52.
3.
Pérez-García, José Manuel, Antonio Llombart‐Cussac, María Gión, et al.. (2021). Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. European Journal of Cancer. 148. 382–394.
4.
Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458.
5.
Antón, Antonio, Isabel Garau, N. Afonso, et al.. (2018). Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. Clinical Breast Cancer. 19(2). 105–112.
6.
Templeton, Arnoud J., Álvaro Rodríguez-Lescure, A. Ruíz, et al.. (2018). Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clinical & Translational Oncology. 20(12). 1548–1556.
7.
Cueva, Juan, Silvia Antolín, Lourdes Calvo, et al.. (2017). Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clinical & Translational Oncology. 19(9). 1067–1078.
8.
Lao, J., Isabel Garau, N. Afonso, et al.. (2016). MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts). Annals of Oncology. 27. vi73–vi73.
9.
Llombart‐Cussac, Antonio, Manuel Ramos, E. Dalmau, et al.. (2016). Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. European Journal of Cancer. 58. 122–129.
10.
Santonja, Ángela, Joan Albanell, Alfonso Sánchez‐Muñoz, et al.. (2016). Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer. Annals of Oncology. 27. vi55–vi55.
11.
Martín, Miguel, Jan C. Brase, Lourdes Calvo, et al.. (2014). Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research. 16(2). R38–R38.
12.
Alba, Emilio, Joan Albanell, Juan de la Haba-Rodríguez, et al.. (2014). Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer. 110(5). 1139–1147.
13.
Alba, Emilio, Lourdes Calvo, Joan Albanell, et al.. (2012). Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Annals of Oncology. 23(12). 3069–3074.
14.
Alba, Emilio, José Ignacio Chacón, Aňa Lluch, et al.. (2012). A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment. 136(2). 487–493.
15.
Antón, A., A. Ruíz, Arrate Plazaola, et al.. (2010). Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology. 22(1). 74–79.
16.
Antolín, Silvia, et al.. (2010). Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine. Clinical & Translational Oncology. 12(6). 450–452.
17.
Martín, Miguel, Amparo Ruı́z, A. Balil, et al.. (2007). Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. The Lancet Oncology. 8(3). 219–225.
18.
Calvo, Lourdes, et al.. (2006). Subacute Cerebellar Degeneration as Paraneoplastic Syndrome: Initial Symptom of Breast Cancer with HER2 Overexpression. Clinical Breast Cancer. 7(1). 79–80.
19.
Martín, Miguel, Aňa Lluch, Miguel Ángel Seguí, et al.. (2006). Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology. 17(8). 1205–1212.
20.
Vorobiof, Daniel, Ulrich R. Kleeberg, R. Pérez-Carrión, et al.. (1999). A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer. Annals of Oncology. 10(10). 1219–1225.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by G. Peruzzotti Breakdown of academic impact, for papers by Laura Pizzuti Breakdown of academic impact, for papers by Stephen P. Anthony Breakdown of academic impact, for papers by Cecilia Nisticò Breakdown of academic impact, for papers by Taher Al‐Tweigeri Breakdown of academic impact, for papers by Volker Möbus Breakdown of academic impact, for papers by Eleni Andreopoulou Breakdown of academic impact, for papers by Paola Papaldo Breakdown of academic impact, for papers by Elizabeth Comen Breakdown of academic impact, for papers by Alexandra Thomas